The Right Drugs at the Right Time for the Right Patient: The MD Anderson Precision Oncology Decision Support Platform

Drug Discov Today. 2015 Dec;20(12):1433-8. doi: 10.1016/j.drudis.2015.05.013. Epub 2015 Jul 3.

Abstract

The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Medical Oncology / methods
  • Neoplasms / drug therapy*
  • Precision Medicine / methods
  • Research

Substances

  • Antineoplastic Agents